|Systematic (IUPAC) name|
|Mol. mass||269.295 g/mol|
Doxanthrine is a synthetic compound which is a potent and selective full agonist for the dopamine D1 receptor. Doxanthrine has been shown to be orally active in producing contralateral rotation in the 6-hydroxy-dopamine rat model of Parkinson's disease.
- Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE (November 2006). "trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist". Journal of Medicinal Chemistry 49 (23): 6848–57.
- Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ (February 2009). "Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 19 (2): 138–46.
- McCorvey, JD, Watts VJ, Nichols DE (July 2012). "Comparison of the D1 dopamine full agonists,dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease". Psychopharmacology (Berl) 222 (1): 81–87.